FLII

Across TCGA pan-cancer cohorts, FLII mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FLII data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FLII mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FLII expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where FLII mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.497	0.822	.007	29	view →
CCRCC	DFS	Median	All	0.531	1.000	.001	25	view →
GBM	DFS	Quartile	All	0.576	0.852	.001	16	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
PDAC	DFS	Tertile	IV	0.203	0.934	.024	6	view →
UCEC	OS	Tertile	III,IV	1.000	0.435	.039	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FLII–LUAD (OS)

Open the LUAD breakdown →